Introduction Combined antiretroviral therapy (cART) has transformed an inexorably fatal disease into a chronic pathology, shifting the focus of research from the control of viral replication to the possibility of HIV cure. Areas covered The present review assesses the principal pharmacological strategies that have been tested for an HIV cure starting from the in vitro proof of concept and the potential rationale of their in vivo applicability. We evaluated the possible pharmacological procedures employed during the early-stage HIV infection and the possibility of cART-free remission. We then analysed the shock and kill approach from the single compounds in vitro mechanism of action, to the in vivo application of single or combined actions. Finally, we briefly considered the novel immunological branch through the discovery and development of broadly neutralizing antibodies in regard of the current and future in vivo therapeutic strategies aiming to verify the clinical applicability of these compounds. Expert opinion Despite an incredible effort in HIV research cure, the likelihood of completely eradicating HIV is unreachable within our current knowledge. A better understanding of the mechanism of viral latency and the fully characterization of HIV reservoir are crucial for the discovery of new therapeutic targets and novel pharmacological entities.
|Titolo:||Clinical pharmacology in HIV cure research : what impact have we seen?|
|Parole Chiave:||HIV; eradication; pharmacology; shock and kill|
|Settore Scientifico Disciplinare:||Settore MED/17 - Malattie Infettive|
|Data di pubblicazione:||2018|
|Data ahead of print / Data di stampa:||20-dic-2018|
|Digital Object Identifier (DOI):||10.1080/17512433.2019.1561272|
|Appare nelle tipologie:||01 - Articolo su periodico|